| Product NDC: | 0310-0284 |
| Proprietary Name: | SEROQUEL |
| Non Proprietary Name: | Quetiapine fumarate |
| Active Ingredient(s): | 400 mg/1 & nbsp; Quetiapine fumarate |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0310-0284 |
| Labeler Name: | AstraZeneca Pharmaceuticals LP |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022047 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20070716 |
| Package NDC: | 0310-0284-94 |
| Package Description: | 4 TABLET, EXTENDED RELEASE in 1 BOTTLE (0310-0284-94) |
| NDC Code | 0310-0284-94 |
| Proprietary Name | SEROQUEL |
| Package Description | 4 TABLET, EXTENDED RELEASE in 1 BOTTLE (0310-0284-94) |
| Product NDC | 0310-0284 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Quetiapine fumarate |
| Dosage Form Name | TABLET, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20070716 |
| Marketing Category Name | NDA |
| Labeler Name | AstraZeneca Pharmaceuticals LP |
| Substance Name | QUETIAPINE FUMARATE |
| Strength Number | 400 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Atypical Antipsychotic [EPC] |